A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05323253|
Recruitment Status : Recruiting
First Posted : April 12, 2022
Last Update Posted : March 14, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Squamous Cell Carcinoma||Device: DaRT seeds||Not Applicable|
This study is a prospective multicenter, pivotal, single arm, open label clinical study to assess the efficacy and safety of intratumoral Alpha DaRT-224 for the treatment of patients with recurrent cutaneous squamous cell carcinoma.
The "Diffusing Alpha-emitter Radiation Therapy (DaRT)", based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life), is described in this study. These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. DaRT seeds will be inserted into recurrent Squamous Cell Carcinoma (SCC) tumors and will be removed following 14-21 days.
The Objective Response Rate (ORR) will be determined based on the confirmed Best Overall Response (BOR) following DaRT insertion. Duration of Response (DOR) will be assessed for up to 6 months from initial response is documented. Safety will be assessed based on the cumulative incidence rate, severity and outcome of device related Adverse Events (AEs). Classification of AEs will be done according to CTCAE v5.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||86 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This is an International Multicenter, Pivotal, Single Arm, Open Label pivotal trial with DaRT for the treatment of Recurrent Cutaneous Squamous Cell Carcinoma|
|Masking:||None (Open Label)|
|Official Title:||A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma|
|Actual Study Start Date :||September 21, 2022|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||December 2025|
Experimental: DaRT seeds
DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Objective Response Rate (ORR) will be determined based on confirmed BOR following DaRT insertion.
Device: DaRT seeds
DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
Other Name: DaRT
- Objective Response Rate [ Time Frame: From Day 14 until 52 weeks ]Objective Response Rate (ORR) of DaRT as treatment for Recurrent SCC established by the confirmed Best Overall Response (BOR), with confirmation at least 4 weeks after initial assessment
- Duration of Response [ Time Frame: 6 months from from first demonstration of CR or PR after Alpha DaRT seeds insertion. ]Assess the Duration of Response (DOR) of DaRT as treatment for Recurrent SCC
- Progression Free Survival [ Time Frame: Up to 12 months after DaRT seed insertion ]Determine Progression Free Survival (PFS) of SCC following DaRT treatment
- Overall Survival [ Time Frame: Up to 12 months following DaRT insertion ]Assess Overall Survival (OS) of Recurrent SCC patients treated with DaRT
- Time of Local Control [ Time Frame: Up to 12 months following DaRT insertion ]Local control of SCC following DaRT treatment is measured as the time from first recorded response (Complete Response/Partial Response/Stable Disease) to local recurrence up to 12 months or last follow up
- Patients Quality of Life Assessment [ Time Frame: On 14 days,12 weeks and 52 weeks following DaRT insertion ]Assess patient reported health related quality of life (QOL) outcomes using the Skin Cancer Index (SCI) and Skindex-16 questionnaires
- DaRT-related Adverse Events [ Time Frame: Up to 12 months following DaRT insertion ]Assess the safety of the Alpha DaRT treatment, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE v5
- Overall Duration of Response (O-DOR) [ Time Frame: Up to 12 months following first reported response ]O-DOR Defined as the time from first response (CR or PR) to the date of initial objectively documented progression or death due to any cause, whichever occurs first.
- User experience [ Time Frame: On Day 0 (DaRT insertion) and Day 14 (+7) (DaRT removal) ]Assess user experience as determined by questionnaire
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients with recurrent cutaneous SCC histologically confirmed who have failed at least first line standard of care therapy who are not indicated for surgery and standard radiation therapy, or non alpha radiation brachytherapy technologies, and for whom no curative systemic treatment is available
- Central histopathological confirmation within 6 months of enrollment provided no tumor treatment occurred between the biopsy and enrollment
- Measurable disease according to RECIST v 1.1.
- Ability to undergo a CT scan
- Tumor size ≤7 cm, at the longest diameter.
- Single lesion per subject.
- Targeted lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds.Targets will be deemed technically amenable for complete coverage if there are entry and exit vectors for placement that are not hindered by bone or major vessels or other vital organs (eg. eye).
- Interstitial implant indication validated by multidisciplinary team.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.
- Life expectancy ≥12 months.
- Subjects male/ female ≥18.
- Willing and have the ability to provide signed Informed Consent.
- Patients, male and female, with reproductive potential (including women who are menopausal for less than a year and not surgically sterilized), must practice acceptable effective methods of birth control, such as barrier methods, condom or diaphragm with spermicide or abstinence. Birth control should be continued for 3 months after the DaRT insertion visit.
- Women with childbearing potential must provide a negative pregnancy test during the screening period and up to V1, prior to the DaRT insertion procedure.
Blood tests values:
- Leucocytes ≥3000mm3,
- Absolute neutrophil count ≥1500mm3,
- Platelets ≥100,000 mm3,
- Total bilirubin ≤ 1.5xULN (upper limit of normal)
- Aspartate Aminotransferase (AST) ≤2.5xULN,
- Serum Glutamic-Oxaloacetic Transaminase (SGOT) ≤2.5xULN,
- Serum Glutamic-Pyruvic Transaminase (SGPT) ≤2.5xULN,
- Alkaline Phosphatase ≤2.5xULN.
- Creatinine ≤ 2.0xULN or Creatinine Clearance ≥60 ml/min.
- INR (International Normalized Ratio) or Prothrombin time ≤1.5xULN.
- Distant or nodal metastatic disease (according to the TNM [tumor, nodes , and metastases] staging system - N+ or M1 patients are excluded).
- T4 disease or perineural spread of disease
- Previously untreated cutaneous SCC indicated for surgery or radiation.
- Mucosal, vulvar, anal and penile SCC.
- Inability to fully cover the entire volume with DaRT seeds
- Inability to place DaRT seeds into tumor due to inaccessibility by presence of bones or major vessels or vital organs
- Inability to undergo a CT scan
- Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.
Patients receiving any of the following within 4 weeks of enrollment:
- Antineoplastic systemic chemotherapy or biological therapy
- Investigational agents other than the study intervention
- Radiation therapy
- Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial.
- Longest tumor diameter >7 cm.
- Tumor with keratoacanthoma histology.
- Known hypersensitivity to any component of treatment.
- Clinically significant cardiovascular disease e.g., cardiac failure of New York Heart Association class III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, history of myocardial infarction in the last 12 months.
- Any medical or Psychiatric illness, which in the opinion of the investigator would compromise the patient's ability to tolerate treatment and to adhere to the clinical trial protocol.
- Serious medical comorbidities that, in the opinion of the investigator, may affect subject compliance and/or interpretation of treatment safety or effectiveness.
- High probability of protocol non-compliance (in opinion of investigator).
- Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry and for 3 months after the DaRT insertion visit.
- Breastfeeding or pregnant women
- Tattoos or other identifying marks which can not be adequately hidden on digital photos
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05323253
|Contact: Liron Dimnik||+972-2-3737-210||LironD@alphatau.com|
|Contact: Aviya Hoidaemail@example.com|
|Responsible Party:||Alpha Tau Medical LTD.|
|Other Study ID Numbers:||
|First Posted:||April 12, 2022 Key Record Dates|
|Last Update Posted:||March 14, 2023|
|Last Verified:||March 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Device Product Not Approved or Cleared by U.S. FDA:||Yes|
|Product Manufactured in and Exported from the U.S.:||No|
Squamous Cell Carcinoma
Recurrent Squamous Cell Carcinoma
Alpha emitting radiation
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell